4-Methylmorpholine → 2-[5-Fluoro-2-(trifluoromethyl)phenyl]-N-{5-[(7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)carbonyl]pyridin-3-yl}acetamide

HRID 82086

Reaktionsgleichung

[F:1][C:2]1[CH:3]=[CH:4][C:5]([C:12]([F:15])([F:14])[F:13])=[C:6]([CH2:8][C:9]([OH:11])=O)[CH:7]=1.CN1CCOCC1.ON1C2C=CC=CC=2N=N1.[NH2:33][C:34]1[CH:35]=[C:36]([C:40]([C:42]2[C:50]3[CH:49]=[N:48][CH:47]=[N:46][C:45]=3[N:44]([CH3:51])[CH:43]=2)=[O:41])[CH:37]=[N:38][CH:39]=1>Cl.CN(C)CCCN=C=NCC>[F:1][C:2]1[CH:3]=[CH:4][C:5]([C:12]([F:15])([F:14])[F:13])=[C:6]([CH2:8][C:9]([NH:33][C:34]2[CH:39]=[N:38][CH:37]=[C:36]([C:40]([C:42]3[C:50]4[CH:49]=[N:48][CH:47]=[N:46][C:45]=4[N:44]([CH3:51])[CH:43]=3)=[O:41])[CH:35]=2)=[O:11])[CH:7]=1

Komponenten

Reaktionsbedingungen

Temperatur: 50 °C

Versuchsvorschrift

1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide HCl (150 μL, 0.5M in DMF) was added to 5-fluoro-2-(trifluoromethyl)phenylacetic acid (90 μmol), N-methylmorpholine (25 μL, 150 μmol), 1-hydroxybenzotriazole (15 μmol, 0.05M in DMF) and (5-aminopyridin-3-yl)(7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)methanone (Preparation 110, 75 μmol, 0.25 M in DMF). The mixture was stirred at 50° C. for 2 hours and then evaporated in vacuo and purified by prep-HPLC (method 4) to afford the title compound.

Aufarbeitung

customevaporated in vacuo
custompurified by prep-HPLC (method 4)

Quellen und Nachweise

ORD-Eintrag: ord-d7c1f637f0a44de9991d5d7951cd7aaf
Quelldatensatz: uspto-grants-2014_09
DOI: 10.6084/m9.figshare.5104873.v1
Patentnummer: US08846698B2

Verknüpfte Notizen

Wird geladen…